"use strict";
/**
 * Known Assets Database - Investment Ready
 *
 * Curated database of known drug assets for key targets.
 * Contains complete deal terms, regulatory designations, and clinical data.
 */
Object.defineProperty(exports, "__esModule", { value: true });
exports.TARGET_DATABASES = exports.GLP1_DATABASE = exports.TL1A_DATABASE = exports.B7H3_DATABASE = void 0;
exports.calculateInvestmentMetrics = calculateInvestmentMetrics;
exports.getTargetDatabase = getTargetDatabase;
exports.findKnownAsset = findKnownAsset;
exports.isExcludedDrug = isExcludedDrug;
exports.getKnownAssetsForTarget = getKnownAssetsForTarget;
exports.isTargetRelatedIntervention = isTargetRelatedIntervention;
// ============================================
// B7-H3 / CD276 Asset Database - COMPLETE
// ============================================
exports.B7H3_DATABASE = {
    target: 'B7-H3',
    aliases: ['B7H3', 'CD276', 'B7-H3/CD276', '4Ig-B7-H3'],
    description: 'Immune checkpoint protein overexpressed in solid tumors. Limited expression on normal tissues makes it attractive ADC target.',
    assets: [
        // ========== ADCs ==========
        {
            primaryName: 'Ifinatamab deruxtecan',
            codeNames: ['DS-7300', 'I-DXd', 'DS-7300a'],
            genericName: 'ifinatamab deruxtecan',
            aliases: ['DS-7300', 'DS-7300a', 'I-DXd', 'DS7300', 'ifinatamab'],
            target: 'B7-H3',
            modality: 'ADC',
            modalityDetail: 'Topoisomerase I inhibitor (DXd/deruxtecan payload)',
            payload: 'DXd (deruxtecan)',
            owner: 'Daiichi Sankyo',
            ownerType: 'Big Pharma',
            partner: 'Merck',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'ES-SCLC (Extensive-Stage Small Cell Lung Cancer)',
            otherIndications: ['NSCLC', 'Solid tumors', 'Breast cancer', 'Prostate cancer'],
            regulatory: { btd: true, odd: true, fastTrack: true, prime: false },
            deal: {
                headline: 'Merck-Daiichi Sankyo collaboration',
                upfront: 4000, // $4B
                equity: 1500, // $1.5B
                milestones: 16500, // $16.5B contingent
                date: '2023-10',
                partner: 'Merck',
                territory: 'Global (co-develop/co-commercialize)',
                notes: 'Includes I-DXd + 2 other Daiichi ADCs. Largest ADC deal ever.',
                source: 'https://www.merck.com/news/merck-and-daiichi-sankyo-enter-global-collaboration/',
                hasBreakdown: true,
            },
            trialIds: ['NCT05280470', 'NCT04145622', 'NCT05104866', 'NCT06362252'],
            keyData: '52% ORR in ES-SCLC; 26% ORR in heavily pretreated solid tumors (ASCO 2024)',
            notes: 'Lead B7-H3 ADC globally. DXd payload proven with Enhertu. Pivotal Phase 3 TROPION-Lung08 ongoing.',
            differentiator: 'Best-in-class DXd payload; deep Merck partnership; most advanced',
        },
        {
            primaryName: 'Risvutatug rezetecan',
            codeNames: ['HS-20093', 'GSK4428859'],
            genericName: 'risvutatug rezetecan',
            aliases: ['HS-20093', 'HS20093', 'GSK4428859', 'GSK\'227'],
            target: 'B7-H3',
            modality: 'ADC',
            modalityDetail: 'Topoisomerase I inhibitor payload',
            payload: 'Topoisomerase I inhibitor',
            owner: 'Hansoh Pharma',
            ownerType: 'Chinese Biotech',
            partner: 'GSK',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'ES-SCLC',
            otherIndications: ['NSCLC', 'Solid tumors'],
            regulatory: { btd: false, odd: false, fastTrack: true, prime: false },
            deal: {
                headline: 'GSK collaboration',
                upfront: 85, // $85M
                milestones: 1525, // $1.525B contingent
                date: '2024-01',
                partner: 'GSK',
                territory: 'Ex-China rights',
                source: 'https://www.gsk.com/en-gb/media/press-releases/',
                hasBreakdown: true,
            },
            trialIds: ['NCT06052423', 'NCT05276609'],
            keyData: '75% ORR in ES-SCLC 2L+ (WCLC 2023); durable responses',
            notes: 'Chinese-origin ADC with strong efficacy data. Phase 3 initiated.',
            differentiator: 'Strong China data; GSK global development; competitive with I-DXd',
        },
        {
            primaryName: 'YL201',
            codeNames: ['YL201'],
            aliases: ['YL-201'],
            target: 'B7-H3',
            modality: 'ADC',
            modalityDetail: 'Topoisomerase I inhibitor (proprietary payload)',
            payload: 'Topo I inhibitor',
            owner: 'MediLink Therapeutics',
            ownerType: 'Chinese Biotech',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'ES-SCLC',
            otherIndications: ['Solid tumors'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT05857684'],
            keyData: '61% ORR in ES-SCLC; 80.6% DCR (ASCO 2024)',
            notes: 'Competitive China ADC with strong Phase 1/2 data. Seeking global partner.',
            differentiator: 'Differentiated payload; strong efficacy',
        },
        {
            primaryName: 'DB-1311',
            codeNames: ['DB-1311', 'BNT324'],
            aliases: ['BNT324', 'DB1311'],
            target: 'B7-H3',
            modality: 'ADC',
            modalityDetail: 'Topoisomerase I inhibitor payload',
            payload: 'Topo I inhibitor',
            owner: 'DualityBio',
            ownerType: 'Chinese Biotech',
            partner: 'BioNTech',
            phase: 'Phase 1/2',
            status: 'Active',
            leadIndication: 'Solid tumors',
            otherIndications: ['SCLC', 'NSCLC'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'BioNTech collaboration',
                upfront: 170, // $170M
                milestones: 1500, // $1.5B contingent
                date: '2024-03',
                partner: 'BioNTech',
                territory: 'Global ex-Greater China',
                source: 'https://www.biontech.com/press/',
                hasBreakdown: true,
            },
            trialIds: ['NCT05914116'],
            keyData: 'Early clinical; BioNTech validation',
            notes: 'BioNTech acquired global rights. Part of broader ADC collaboration.',
            differentiator: 'BioNTech partnership; mRNA combo potential',
        },
        {
            primaryName: 'MHB088C',
            codeNames: ['MHB088C'],
            aliases: ['MHB-088C'],
            target: 'B7-H3',
            modality: 'ADC',
            modalityDetail: 'ADC with undisclosed payload',
            owner: 'Minghui Pharmaceuticals',
            ownerType: 'Chinese Biotech',
            partner: 'Qilu Pharmaceutical',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Solid tumors',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Qilu Pharmaceutical collaboration (China)',
                upfront: 6, // ~45M RMB = ~$6M
                milestones: 179, // ~1.3B RMB = ~$179M contingent
                date: '2024-04',
                partner: 'Qilu Pharmaceutical',
                territory: 'Greater China',
                notes: 'RMB deal: 45M RMB upfront + 1.3B RMB milestones',
                hasBreakdown: true,
            },
            trialIds: ['NCT05865470'],
            notes: 'China-focused ADC program.',
            differentiator: 'China market focus',
        },
        {
            primaryName: 'Vobramitamab duocarmazine',
            codeNames: ['MGC018'],
            genericName: 'vobramitamab duocarmazine',
            aliases: ['MGC018', 'MGC-018', 'vobramitamab'],
            target: 'B7-H3',
            modality: 'ADC',
            modalityDetail: 'Duocarmazine DNA alkylating payload',
            payload: 'Duocarmazine',
            owner: 'MacroGenics',
            ownerType: 'Biotech',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'mCRPC (Metastatic Castration-Resistant Prostate Cancer)',
            otherIndications: ['Solid tumors', 'NSCLC', 'Triple-negative breast cancer'],
            regulatory: { btd: false, odd: false, fastTrack: true, prime: false },
            trialIds: ['NCT03729596', 'NCT04086368'],
            keyData: '40% PSA50 response rate in mCRPC; differentiated prostate focus',
            notes: 'Only B7-H3 ADC with duocarmazine payload. Prostate cancer focus differentiates.',
            differentiator: 'Unique payload; prostate cancer focus; less competitive landscape',
        },
        {
            primaryName: 'BA3011',
            codeNames: ['BA3011', 'CAB-B7-H3-ADC'],
            aliases: ['CAB-B7-H3-ADC'],
            target: 'B7-H3',
            modality: 'ADC',
            modalityDetail: 'Conditionally Active Biologic (CAB) with MMAE payload',
            payload: 'MMAE',
            owner: 'BioAtla',
            ownerType: 'Biotech',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Solid tumors',
            otherIndications: ['Sarcoma', 'NSCLC'],
            regulatory: { btd: false, odd: true, fastTrack: false, prime: false },
            trialIds: ['NCT03872947'],
            keyData: 'CAB technology enables tumor-selective activation',
            notes: 'Conditionally active - only activates in tumor microenvironment.',
            differentiator: 'CAB technology for improved therapeutic window',
        },
        {
            primaryName: 'JS203',
            codeNames: ['JS203'],
            aliases: ['JS-203'],
            target: 'B7-H3',
            modality: 'ADC',
            modalityDetail: 'ADC with proprietary payload',
            owner: 'Junshi Biosciences',
            ownerType: 'Chinese Biotech',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Solid tumors',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT05252390'],
            notes: 'Early-stage China ADC program.',
            differentiator: 'Junshi platform',
        },
        {
            primaryName: 'SHR-3680',
            codeNames: ['SHR-3680'],
            aliases: ['SHR3680'],
            target: 'B7-H3',
            modality: 'ADC',
            owner: 'Hengrui Medicine',
            ownerType: 'Chinese Biotech',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Solid tumors',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            notes: 'Hengrui B7-H3 ADC program.',
            differentiator: 'Hengrui capabilities',
        },
        // ========== Monoclonal Antibodies ==========
        {
            primaryName: 'Enoblituzumab',
            codeNames: ['MGA271'],
            genericName: 'enoblituzumab',
            aliases: ['MGA271', 'MGA-271'],
            target: 'B7-H3',
            modality: 'mAb',
            modalityDetail: 'Fc-enhanced humanized IgG1 monoclonal antibody',
            owner: 'MacroGenics',
            ownerType: 'Biotech',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'HNSCC (Head and Neck Squamous Cell Carcinoma)',
            otherIndications: ['Prostate cancer', 'Pediatric solid tumors', 'Melanoma'],
            regulatory: { btd: false, odd: true, fastTrack: false, prime: false },
            trialIds: ['NCT02475213', 'NCT02923180'],
            keyData: 'Fc-enhanced for ADCC; combination with retifanlimab (PD-1)',
            notes: 'Being studied in combination with PD-1 inhibitor retifanlimab.',
            differentiator: 'Fc-enhanced ADCC; IO combination approach',
        },
        {
            primaryName: 'TQB2103',
            codeNames: ['TQB2103'],
            aliases: ['TQB-2103'],
            target: 'B7-H3',
            modality: 'mAb',
            owner: 'Chia Tai Tianqing',
            ownerType: 'Chinese Biotech',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Solid tumors',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            notes: 'Chinese B7-H3 antibody program.',
            differentiator: 'China market',
        },
        // ========== Bispecifics ==========
        {
            primaryName: 'MGD024',
            codeNames: ['MGD024'],
            aliases: ['MGD-024'],
            target: 'B7-H3 x CD3',
            modality: 'Bispecific',
            modalityDetail: 'DART (Dual-Affinity Re-Targeting) B7-H3 x CD3 bispecific',
            owner: 'MacroGenics',
            ownerType: 'Biotech',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Solid tumors',
            otherIndications: ['Pediatric solid tumors'],
            regulatory: { btd: false, odd: true, fastTrack: false, prime: false },
            trialIds: ['NCT05440500'],
            notes: 'Next-generation DART bispecific. Successor to MGD009.',
            differentiator: 'DART platform; T-cell engagement',
        },
        {
            primaryName: 'Orlotamab',
            codeNames: ['MGD009'],
            genericName: 'orlotamab',
            aliases: ['MGD009', 'MGD-009'],
            target: 'B7-H3 x CD3',
            modality: 'Bispecific',
            modalityDetail: 'DART B7-H3 x CD3 bispecific (first-gen)',
            owner: 'MacroGenics',
            ownerType: 'Biotech',
            phase: 'Phase 1',
            status: 'On Hold',
            leadIndication: 'Solid tumors',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT02628535'],
            notes: 'Development paused. MGD024 is successor.',
            differentiator: 'First-gen DART; development paused',
        },
        {
            primaryName: 'PT217',
            codeNames: ['PT217'],
            aliases: [],
            target: 'B7-H3 x 4-1BB',
            modality: 'Bispecific',
            modalityDetail: 'B7-H3 x 4-1BB bispecific antibody',
            owner: 'Phanes Therapeutics',
            ownerType: 'Biotech',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Solid tumors',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            notes: 'Novel 4-1BB costimulation approach.',
            differentiator: '4-1BB costimulation',
        },
        // ========== Radioconjugates ==========
        {
            primaryName: 'Omburtamab',
            codeNames: ['8H9', 'Burtomab'],
            genericName: 'omburtamab',
            aliases: ['131I-omburtamab', 'I-131 omburtamab', '8H9', 'Burtomab'],
            target: 'B7-H3',
            modality: 'Radioconjugate',
            modalityDetail: 'Iodine-131 labeled monoclonal antibody (radioimmunotherapy)',
            payload: 'Iodine-131',
            owner: 'Y-mAbs Therapeutics',
            ownerType: 'Biotech',
            phase: 'Filed',
            status: 'Active',
            leadIndication: 'CNS/leptomeningeal metastases from neuroblastoma',
            otherIndications: ['Medulloblastoma', 'DIPG (Diffuse Intrinsic Pontine Glioma)', 'Brain metastases'],
            regulatory: { btd: true, odd: true, fastTrack: false, prime: true, rmat: true },
            trialIds: ['NCT03275402', 'NCT01502917', 'NCT05064306'],
            keyData: 'BLA filed Oct 2022; PDUFA extended; Phase 3 for DIPG',
            notes: 'First-in-class radioimmunotherapy for CNS tumors. BLA under review.',
            differentiator: 'Only radioconjugate; CNS penetration; pediatric focus',
        },
        // ========== CAR-T ==========
        {
            primaryName: '4SCAR-276',
            codeNames: ['4SCAR-276'],
            aliases: ['B7-H3 CAR-T Stanford'],
            target: 'B7-H3',
            modality: 'CAR-T',
            modalityDetail: '4th generation CAR-T targeting B7-H3',
            owner: 'Stanford University',
            ownerType: 'Academic',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Pediatric solid tumors',
            otherIndications: ['Neuroblastoma', 'Osteosarcoma'],
            regulatory: { btd: false, odd: true, fastTrack: false, prime: false },
            trialIds: ['NCT04483778'],
            notes: 'Academic CAR-T program with encouraging early signals.',
            differentiator: 'Academic; pediatric focus; 4th gen CAR',
        },
        {
            primaryName: 'SCRI-CARB7H3',
            codeNames: ['SCRI-CARB7H3'],
            aliases: ['Seattle B7-H3 CAR-T', 'B7-H3 CAR-T Seattle'],
            target: 'B7-H3',
            modality: 'CAR-T',
            modalityDetail: 'CAR-T for CNS tumors with intrathecal delivery',
            owner: "Seattle Children's Research Institute",
            ownerType: 'Academic',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Medulloblastoma',
            otherIndications: ['DIPG', 'CNS tumors', 'Ependymoma'],
            regulatory: { btd: false, odd: true, fastTrack: false, prime: false },
            trialIds: ['NCT04185038', 'NCT04897321'],
            keyData: 'Intrathecal delivery for CNS penetration',
            notes: 'Pioneering intrathecal CAR-T delivery for brain tumors.',
            differentiator: 'CNS administration; pediatric CNS tumors',
        },
        {
            primaryName: 'TAA06',
            codeNames: ['TAA06'],
            aliases: [],
            target: 'B7-H3',
            modality: 'CAR-T',
            modalityDetail: 'Autologous B7-H3 CAR-T',
            owner: 'PersonGen BioTherapeutics',
            ownerType: 'Chinese Biotech',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Solid tumors',
            otherIndications: ['Lung cancer', 'Ovarian cancer'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT04432649'],
            notes: 'Chinese CAR-T program advancing in solid tumors.',
            differentiator: 'China CAR-T leader',
        },
        {
            primaryName: 'LM-302',
            codeNames: ['LM-302'],
            aliases: ['LM302'],
            target: 'B7-H3',
            modality: 'CAR-T',
            modalityDetail: 'Autologous B7-H3 CAR-T',
            owner: 'Legend Biotech',
            ownerType: 'Chinese Biotech',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Solid tumors',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            notes: 'Legend Biotech B7-H3 CAR-T (same company as Carvykti).',
            differentiator: 'Legend platform expertise (Carvykti approved)',
        },
        {
            primaryName: 'B7-H3 CAR-T (NCI)',
            codeNames: ['NCI-B7H3-CAR'],
            aliases: [],
            target: 'B7-H3',
            modality: 'CAR-T',
            modalityDetail: 'NCI-developed B7-H3 CAR-T',
            owner: 'National Cancer Institute',
            ownerType: 'Academic',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Pediatric solid tumors',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT04897321'],
            notes: 'NCI-sponsored pediatric program.',
            differentiator: 'NCI expertise; pediatric focus',
        },
        {
            primaryName: 'C7R-GD2/B7-H3 CAR-T',
            codeNames: ['C7R-GD2-B7H3'],
            aliases: ['Dual CAR-T GD2/B7-H3'],
            target: 'B7-H3 + GD2',
            modality: 'CAR-T',
            modalityDetail: 'Dual-targeting CAR-T (GD2 + B7-H3) with C7R cytokine support',
            owner: 'Baylor College of Medicine',
            ownerType: 'Academic',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Neuroblastoma',
            otherIndications: ['Pediatric solid tumors'],
            regulatory: { btd: false, odd: true, fastTrack: false, prime: false },
            trialIds: ['NCT04897321'],
            notes: 'Dual targeting to prevent antigen escape.',
            differentiator: 'Dual targeting; cytokine armored',
        },
        // ========== Combinations ==========
        {
            primaryName: 'DS-7300 + Pembrolizumab',
            codeNames: ['I-DXd + Keytruda'],
            aliases: ['DS-7300 + pembro', 'I-DXd + pembrolizumab'],
            target: 'B7-H3',
            modality: 'ADC',
            modalityDetail: 'B7-H3 ADC + PD-1 combination',
            owner: 'Daiichi Sankyo',
            ownerType: 'Big Pharma',
            partner: 'Merck',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'NSCLC',
            otherIndications: ['ES-SCLC'],
            regulatory: { btd: false, odd: false, fastTrack: true, prime: false },
            trialIds: ['NCT05280470'],
            keyData: 'Pivotal combination study in lung cancer',
            notes: 'Key combination strategy under Merck partnership.',
            differentiator: 'IO combination; Merck partnership',
        },
        {
            primaryName: 'Enoblituzumab + Retifanlimab',
            codeNames: ['MGA271 + INCMGA00012'],
            aliases: ['enoblituzumab combo', 'MGA271 combo'],
            target: 'B7-H3',
            modality: 'mAb',
            modalityDetail: 'B7-H3 mAb + PD-1 combination',
            owner: 'MacroGenics',
            ownerType: 'Biotech',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'HNSCC',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT02475213'],
            notes: 'B7-H3 mAb combined with PD-1 inhibitor.',
            differentiator: 'IO combination approach',
        },
    ],
    excludedDrugs: [
        // Generic chemotherapy
        'cyclophosphamide', 'fludarabine', 'bendamustine', 'temozolomide',
        'cisplatin', 'carboplatin', 'oxaliplatin', 'etoposide', 'irinotecan',
        'docetaxel', 'paclitaxel', 'gemcitabine', 'pemetrexed', 'vinblastine',
        'doxorubicin', 'epirubicin', 'methotrexate', 'cytarabine', 'azacitidine',
        'capecitabine', 'vinorelbine', 'topotecan', 'vincristine',
        // Standard checkpoint inhibitors
        'pembrolizumab', 'nivolumab', 'atezolizumab', 'durvalumab', 'avelumab',
        'ipilimumab', 'tremelimumab', 'cemiplimab', 'dostarlimab', 'retifanlimab',
        // Supportive care
        'dexamethasone', 'prednisone', 'methylprednisolone', 'hydrocortisone',
        'ondansetron', 'granisetron', 'palonosetron', 'aprepitant',
        'filgrastim', 'pegfilgrastim', 'epoetin', 'darbepoetin',
        // Other common trial drugs
        'placebo', 'standard of care', 'best supportive care',
        'leucovorin', 'mesna', 'zoledronic acid',
    ],
    excludedSponsors: [],
};
// ============================================
// TL1A / TNFSF15 Asset Database - COMPLETE
// ============================================
exports.TL1A_DATABASE = {
    target: 'TL1A',
    aliases: ['TL1A', 'TNFSF15', 'TL-1A', 'TNF-like ligand 1A', 'VEGI'],
    description: 'TNF superfamily cytokine implicated in IBD pathogenesis. TL1A promotes Th1/Th17 responses and fibrosis. Hot target for Crohn\'s disease and ulcerative colitis.',
    assets: [
        // ========== Monoclonal Antibodies ==========
        {
            primaryName: 'Tulisokibart (PRA023, MK-7240)',
            codeNames: ['PRA023', 'MK-7240', 'tulisokibart'],
            genericName: 'tulisokibart',
            aliases: ['PRA023', 'PRA-023', 'MK-7240', 'MK7240', 'Tulisokibart'],
            target: 'TL1A',
            modality: 'mAb',
            modalityDetail: 'Fully human IgG1 anti-TL1A monoclonal antibody',
            owner: 'Merck',
            ownerType: 'Big Pharma',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'Ulcerative Colitis',
            otherIndications: ['Crohn\'s Disease', 'IBD'],
            regulatory: { btd: true, odd: false, fastTrack: true, prime: false },
            deal: {
                headline: 'Merck acquisition of Prometheus',
                upfront: 10800, // $10.8B all-cash acquisition
                equity: 0,
                milestones: 0, // Full acquisition, no milestones
                date: '2023-04',
                partner: 'Prometheus Biosciences (acquired)',
                territory: 'Global',
                notes: 'Merck acquired Prometheus Biosciences for $10.8B to gain tulisokibart',
                source: 'https://www.merck.com/news/merck-to-acquire-prometheus-biosciences/',
                hasBreakdown: true,
            },
            trialIds: ['NCT05668013', 'NCT05499130', 'NCT06097481'],
            keyData: '26% remission (25% placebo-adj) in TL1A-high patients; 49% endoscopic improvement (NEJM 2024)',
            notes: 'Lead TL1A inhibitor. Prometheus acquired by Merck for $10.8B. Precision medicine approach with biomarker selection.',
            differentiator: 'Most advanced; Merck resources; precision medicine strategy',
            efficacyData: {
                endpoint: 'Clinical Remission',
                result: 26,
                placebo: 1,
                placeboAdjusted: 25,
                trial: 'ARTEMIS-UC',
                timepoint: 'Week 12',
                population: 'TL1A-high biomarker positive',
                source: 'NEJM 2024',
            },
            differentiators: {
                strategy: 'Precision medicine',
                dosing: '1000mg â†’ 500mg Q4W SC',
                biomarker: 'Yes (TL1A-high)',
                halfLife: '~14 days',
                beyondIndication: 'SSc-ILD, RA explored',
            },
            investmentThesis: 'Most advanced TL1A with Merck backing; precision medicine with biomarker selection may yield enriched responses; $10.8B acquisition validates target',
        },
        {
            primaryName: 'Afimkibart (RVT-3101, RG6631)',
            codeNames: ['RVT-3101', 'RG6631', 'afimkibart'],
            genericName: 'afimkibart',
            aliases: ['RVT3101', 'RG-6631', 'RVT-3101', 'Afimkibart'],
            target: 'TL1A',
            modality: 'mAb',
            modalityDetail: 'Fully human IgG1 anti-TL1A monoclonal antibody',
            owner: 'Roche',
            ownerType: 'Big Pharma',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'Ulcerative Colitis',
            otherIndications: ['Crohn\'s Disease'],
            regulatory: { btd: false, odd: false, fastTrack: true, prime: false },
            deal: {
                headline: 'Roche acquisition from Roivant',
                upfront: 7250, // $7.25B deal
                equity: 0,
                milestones: 0, // Full acquisition of Telavant
                date: '2023-10',
                partner: 'Roivant/Telavant (acquired)',
                territory: 'Global',
                notes: 'Roche acquired Telavant (Roivant JV with Pfizer) for $7.25B',
                source: 'https://www.roche.com/media/releases/',
                hasBreakdown: true,
            },
            trialIds: ['NCT05668039', 'NCT06194695'],
            keyData: '70% clinical response, 35% remission in UC Phase 2 (ACG 2023)',
            notes: 'Originally from Pfizer. Roche acquired Telavant to get afimkibart.',
            differentiator: 'Roche development; multi-indication expansion potential',
            efficacyData: {
                endpoint: 'Clinical Remission',
                result: 35,
                placebo: 12,
                placeboAdjusted: 23,
                trial: 'Phase 2',
                timepoint: 'Week 14',
                source: 'ACG 2023',
            },
            differentiators: {
                strategy: 'Multi-indication expansion',
                dosing: '150mg Q4W SC',
                biomarker: 'No',
                halfLife: '~14 days',
                beyondIndication: 'AD, MASH, Celiac potential',
            },
            investmentThesis: 'Roche backing with $7.25B acquisition validates asset; multi-indication expansion strategy differentiates from IBD-only competitors',
        },
        {
            primaryName: 'Duvakitug (TEV-48574, SAR447189)',
            codeNames: ['TEV-48574', 'SAR447189', 'duvakitug'],
            genericName: 'duvakitug',
            aliases: ['TEV48574', 'SAR-447189', 'TEV-48574', 'Duvakitug'],
            target: 'TL1A',
            modality: 'mAb',
            modalityDetail: 'Fully human IgG1 anti-TL1A monoclonal antibody',
            owner: 'Teva',
            ownerType: 'Big Pharma',
            partner: 'Sanofi',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Ulcerative Colitis',
            otherIndications: ['Crohn\'s Disease'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Sanofi collaboration',
                upfront: 500, // $500M upfront
                equity: 0,
                milestones: 1000, // ~$1B+ in milestones
                date: '2023-12',
                partner: 'Sanofi',
                territory: 'Global (Sanofi has commercialization rights)',
                notes: 'Sanofi/Teva collaboration for TL1A program',
                source: 'https://www.sanofi.com/en/media-room/press-releases/',
                hasBreakdown: true,
            },
            trialIds: ['NCT05774587'],
            keyData: '47.8% remission (27.4% placebo-adj) at 1000mg Q4W - BEST IN CLASS (DDW 2024)',
            notes: 'Highest placebo-adjusted remission rate in the class. Sanofi partnered for global commercialization.',
            differentiator: 'Best-in-class efficacy data; Sanofi commercialization power',
            efficacyData: {
                endpoint: 'Clinical Remission',
                result: 47.8,
                placebo: 20.4,
                placeboAdjusted: 27.4,
                trial: 'RELIEVE UCCD',
                timepoint: 'Week 14',
                source: 'DDW 2024',
            },
            differentiators: {
                strategy: 'Best-in-class efficacy',
                dosing: '500-1000mg Q4W SC',
                biomarker: 'No',
                halfLife: '~21 days',
                beyondIndication: 'IBD only',
            },
            investmentThesis: 'Highest placebo-adjusted remission (27.4%) in the class; Sanofi commercialization muscle; potential best-in-class positioning',
        },
        {
            primaryName: 'PF-06480605',
            codeNames: ['PF-06480605'],
            aliases: ['PF06480605'],
            target: 'TL1A',
            modality: 'mAb',
            modalityDetail: 'Anti-TL1A monoclonal antibody (IgG1)',
            owner: 'Pfizer',
            ownerType: 'Big Pharma',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Ulcerative Colitis',
            otherIndications: ['Crohn\'s Disease'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT04090411', 'NCT05286411'],
            keyData: 'Phase 2 TUSCANY study ongoing',
            notes: 'Pfizer internal program. RVT-3101 was originally out-licensed from Pfizer.',
            differentiator: 'Pfizer resources; internal development',
        },
        {
            primaryName: 'ABBV-274',
            codeNames: ['ABBV-274'],
            aliases: [],
            target: 'TL1A',
            modality: 'mAb',
            modalityDetail: 'Anti-TL1A monoclonal antibody',
            owner: 'AbbVie',
            ownerType: 'Big Pharma',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Ulcerative Colitis',
            otherIndications: ['Crohn\'s Disease', 'IBD'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT05724979'],
            notes: 'AbbVie entering TL1A space to defend IBD franchise.',
            differentiator: 'AbbVie IBD expertise (Humira, Skyrizi, Rinvoq)',
        },
        {
            primaryName: 'DC-806',
            codeNames: ['DC-806'],
            aliases: ['DC806'],
            target: 'TL1A',
            modality: 'mAb',
            modalityDetail: 'Anti-TL1A monoclonal antibody',
            owner: 'Dualitas Bio',
            ownerType: 'Biotech',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Crohn\'s Disease',
            otherIndications: ['Ulcerative Colitis'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            notes: 'Biotech developing TL1A antibody.',
            differentiator: 'Biotech approach',
        },
        {
            primaryName: 'ANB032',
            codeNames: ['ANB032'],
            aliases: ['ANB-032'],
            target: 'TL1A',
            modality: 'mAb',
            modalityDetail: 'Anti-TL1A monoclonal antibody',
            owner: 'AnaptysBio',
            ownerType: 'Biotech',
            partner: 'GSK',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Inflammatory diseases',
            otherIndications: ['IBD', 'Atopic dermatitis'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'GSK collaboration',
                upfront: 45, // $45M upfront
                equity: 0,
                milestones: 500, // Up to $500M+ milestones
                date: '2023-06',
                partner: 'GSK',
                territory: 'Global (GSK option)',
                notes: 'GSK has option to acquire rights',
                source: 'https://www.anaptysbio.com/',
                hasBreakdown: true,
            },
            trialIds: [],
            keyData: 'GSK partnered for development',
            notes: 'AnaptysBio program partnered with GSK.',
            differentiator: 'GSK partnership',
        },
        // ========== Bispecifics ==========
        {
            primaryName: 'SAR443765 (TL1A x IL-23 Bispecific)',
            codeNames: ['SAR443765'],
            aliases: ['SAR-443765'],
            target: 'TL1A x IL-23',
            modality: 'Bispecific',
            modalityDetail: 'Bispecific antibody targeting TL1A and IL-23 p19',
            owner: 'Sanofi',
            ownerType: 'Big Pharma',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Crohn\'s Disease',
            otherIndications: ['Ulcerative Colitis', 'IBD'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT05719701'],
            keyData: 'First-in-class bispecific combining two validated IBD targets',
            notes: 'Novel bispecific targeting both TL1A and IL-23 pathways for potentially superior efficacy.',
            differentiator: 'First TL1A bispecific; dual mechanism may provide best-in-class efficacy',
            differentiators: {
                strategy: 'Dual-target synergy',
                dosing: 'TBD',
                biomarker: 'No',
                halfLife: 'TBD',
                beyondIndication: 'IBD focus',
            },
            investmentThesis: 'First-in-class bispecific combining TL1A + IL-23 blockade; potential for superior efficacy vs. monospecifics; Sanofi development resources',
        },
        // NOTE: Removed false positives after verification:
        // - NM26: Actually targets IL-31, not TL1A (Numab)
        // - OSE-703: Actually targets CD127/IL-7R, not TL1A (OSE Immunotherapeutics)
        // - CNTE-0532: Cannot verify this drug exists (Connect Biopharma)
    ],
    excludedDrugs: [
        // Generic IBD drugs
        'mesalamine', 'sulfasalazine', 'balsalazide', 'olsalazine',
        'budesonide', 'prednisone', 'methylprednisolone', 'hydrocortisone',
        'azathioprine', 'mercaptopurine', '6-mp', 'methotrexate',
        // Approved biologics (not TL1A-specific)
        'infliximab', 'adalimumab', 'certolizumab', 'golimumab', 'vedolizumab',
        'ustekinumab', 'risankizumab', 'mirikizumab', 'guselkumab',
        'tofacitinib', 'upadacitinib', 'filgotinib', 'ozanimod', 'etrasimod',
        // FALSE POSITIVES - drugs that do NOT target TL1A (verified 2024-01)
        'NM26', // Numab - actually targets IL-31, not TL1A
        'OSE-703', // OSE Immunotherapeutics - actually targets CD127/IL-7R, not TL1A
        'CNTE-0532', // Connect Biopharma - cannot verify this drug exists
    ],
    excludedSponsors: [],
};
// ============================================
// GLP-1 Asset Database - COMPLETE
// ============================================
exports.GLP1_DATABASE = {
    target: 'GLP-1',
    aliases: ['GLP-1', 'GLP1', 'GLP-1R', 'glucagon-like peptide-1', 'incretin'],
    description: 'GLP-1 receptor agonists for diabetes and obesity. Blockbuster drug class with >$50B annual market. Hot area for oral formulations and next-gen multi-agonists.',
    assets: [
        // ========== APPROVED ==========
        {
            primaryName: 'Semaglutide (Ozempic/Wegovy/Rybelsus)',
            codeNames: ['NN9535', 'Ozempic', 'Wegovy', 'Rybelsus'],
            genericName: 'semaglutide',
            aliases: ['semaglutide', 'ozempic', 'wegovy', 'rybelsus', 'NN9535'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Peptide GLP-1 Agonist',
            owner: 'Novo Nordisk',
            ownerType: 'Big Pharma',
            phase: 'Approved',
            status: 'Active',
            leadIndication: 'T2D, Obesity, CV Risk',
            otherIndications: ['MASH', 'CKD'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT03548935', 'NCT03574597'],
            keyData: '~15-17% weight loss (Wegovy); FLOW: 24% kidney risk reduction',
            notes: 'Market leader, first oral Wegovy approved Dec 2025',
            differentiator: 'Market leader; multiple formulations (SC/oral); proven CV and renal benefits',
        },
        {
            primaryName: 'Tirzepatide (Mounjaro/Zepbound)',
            codeNames: ['LY3298176', 'Mounjaro', 'Zepbound'],
            genericName: 'tirzepatide',
            aliases: ['tirzepatide', 'mounjaro', 'zepbound', 'LY3298176'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual Peptide GLP-1/GIP Agonist',
            owner: 'Eli Lilly',
            ownerType: 'Big Pharma',
            phase: 'Approved',
            status: 'Active',
            leadIndication: 'T2D, Obesity',
            otherIndications: ['HFpEF', 'OSA'],
            regulatory: { btd: true, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT04184622', 'NCT04657003'],
            keyData: '~21-22.5% weight loss; SUMMIT: 33% CV death/HF reduction',
            notes: 'Best-in-class efficacy for weight loss',
            differentiator: 'Best-in-class weight loss; dual GLP-1/GIP mechanism',
        },
        {
            primaryName: 'Liraglutide (Victoza/Saxenda)',
            codeNames: ['NN2211', 'Victoza', 'Saxenda'],
            genericName: 'liraglutide',
            aliases: ['liraglutide', 'victoza', 'saxenda', 'NN2211'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Peptide GLP-1 Agonist',
            owner: 'Novo Nordisk',
            ownerType: 'Big Pharma',
            phase: 'Approved',
            status: 'Active',
            leadIndication: 'T2D, Obesity',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            keyData: '~8% weight loss',
            notes: 'First-gen, now generic competition',
            differentiator: 'First-gen; daily dosing',
        },
        {
            primaryName: 'Dulaglutide (Trulicity)',
            codeNames: ['LY2189265', 'Trulicity'],
            genericName: 'dulaglutide',
            aliases: ['dulaglutide', 'trulicity', 'LY2189265'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Peptide GLP-1 Agonist',
            owner: 'Eli Lilly',
            ownerType: 'Big Pharma',
            phase: 'Approved',
            status: 'Active',
            leadIndication: 'T2D',
            otherIndications: ['CV risk reduction'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            keyData: 'REWIND: 12% CV risk reduction',
            notes: 'Major T2D market share',
            differentiator: 'Weekly dosing; CV benefit',
        },
        {
            primaryName: 'Exenatide (Byetta/Bydureon)',
            codeNames: ['AC2993', 'Byetta', 'Bydureon'],
            genericName: 'exenatide',
            aliases: ['exenatide', 'byetta', 'bydureon', 'AC2993'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Peptide GLP-1 Agonist',
            owner: 'AstraZeneca',
            ownerType: 'Big Pharma',
            phase: 'Approved',
            status: 'Active',
            leadIndication: 'T2D',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            keyData: 'Modest efficacy',
            notes: 'First-gen, declining use',
            differentiator: 'First exendin-based GLP-1',
        },
        {
            primaryName: 'Mazdutide',
            codeNames: ['IBI362', 'LY3305677'],
            genericName: 'mazdutide',
            aliases: ['mazdutide', 'IBI362', 'LY3305677'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual Peptide GCG/GLP-1 Agonist',
            owner: 'Innovent Biologics',
            ownerType: 'Chinese Biotech',
            partner: 'Eli Lilly (ex-China)',
            phase: 'Approved',
            status: 'Active',
            leadIndication: 'Obesity, T2D',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            keyData: 'GLORY-1: 14.8% (6mg), GLORY-2: 20.1% (9mg)',
            notes: 'First-in-class dual GCG/GLP-1 approved; beat semaglutide head-to-head',
            differentiator: 'First dual GCG/GLP-1 approved; China leader',
        },
        // ========== PHASE 3 ==========
        {
            primaryName: 'Orforglipron',
            codeNames: ['LY3502970'],
            genericName: 'orforglipron',
            aliases: ['orforglipron', 'LY3502970'],
            target: 'GLP-1',
            modality: 'Small Molecule',
            modalityDetail: 'Small Molecule GLP-1 Agonist',
            owner: 'Eli Lilly',
            ownerType: 'Big Pharma',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'Obesity, T2D',
            otherIndications: ['NASH'],
            regulatory: { btd: false, odd: false, fastTrack: true, prime: false },
            trialIds: ['NCT05869903', 'NCT05803421'],
            keyData: 'Phase 2: 14.7% weight loss at 36 weeks',
            notes: 'Lead oral small molecule; ACHIEVE trials ongoing',
            differentiator: 'First oral small molecule GLP-1; convenience over peptides',
        },
        {
            primaryName: 'CagriSema',
            codeNames: ['NN9838'],
            aliases: ['CagriSema', 'cagrilintide + semaglutide', 'NN9838'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Peptide Combination (GLP-1 + Amylin)',
            owner: 'Novo Nordisk',
            ownerType: 'Big Pharma',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'Obesity',
            otherIndications: ['T2D'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT05567796'],
            keyData: 'Phase 2: ~15.6% weight loss at 32 weeks',
            notes: 'Semaglutide + cagrilintide combination',
            differentiator: 'Dual mechanism (GLP-1 + amylin); Novo combination strategy',
        },
        {
            primaryName: 'Retatrutide',
            codeNames: ['LY3437943'],
            genericName: 'retatrutide',
            aliases: ['retatrutide', 'LY3437943'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Triple Peptide Agonist (GLP-1/GIP/GCGR)',
            owner: 'Eli Lilly',
            ownerType: 'Big Pharma',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'Obesity',
            otherIndications: ['T2D', 'MASH', 'OSA'],
            regulatory: { btd: false, odd: false, fastTrack: true, prime: false },
            trialIds: ['NCT05929066', 'NCT05881759'],
            keyData: 'Phase 2: ~24% weight loss at 48 weeks',
            notes: 'Highest weight loss reported; could be best-in-class',
            differentiator: 'Triple agonist; highest weight loss ever reported; potential best-in-class',
        },
        {
            primaryName: 'Survodutide',
            codeNames: ['BI 456906'],
            genericName: 'survodutide',
            aliases: ['survodutide', 'BI456906', 'BI 456906'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual Peptide GCGR/GLP-1 Agonist',
            owner: 'Boehringer Ingelheim',
            ownerType: 'Big Pharma',
            partner: 'Zealand Pharma',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'Obesity, MASH',
            otherIndications: ['T2D'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Licensed from Zealand Pharma',
                partner: 'Zealand Pharma',
                hasBreakdown: false,
            },
            trialIds: ['NCT05972967', 'NCT05486039'],
            keyData: 'Phase 2: ~19% weight loss; 83% MASH improvement',
            notes: 'Strong MASH data differentiator',
            differentiator: 'Strong MASH efficacy; differentiated liver indication',
        },
        {
            primaryName: 'VK2735',
            codeNames: ['VK2735'],
            aliases: ['VK2735', 'VK-2735'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual Peptide GLP-1/GIP Agonist',
            owner: 'Viking Therapeutics',
            ownerType: 'Biotech',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'Obesity',
            otherIndications: ['MASH'],
            regulatory: { btd: false, odd: false, fastTrack: true, prime: false },
            trialIds: ['NCT06272643'],
            keyData: 'Phase 2: 14.7% at 13 weeks (highest dose)',
            notes: 'VANQUISH Phase 3 program',
            differentiator: 'Biotech speed; attractive M&A target',
        },
        {
            primaryName: 'MariTide',
            codeNames: ['AMG 133'],
            aliases: ['MariTide', 'AMG133', 'AMG 133'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Bispecific Antibody-Peptide (GLP-1R agonist + GIPR antagonist)',
            owner: 'Amgen',
            ownerType: 'Big Pharma',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'Obesity',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT06399887'],
            keyData: 'Phase 2: ~20% weight loss with monthly dosing',
            notes: 'Unique monthly dosing; GIP antagonism approach',
            differentiator: 'Monthly dosing; unique GIP antagonist mechanism',
        },
        {
            primaryName: 'HRS9531',
            codeNames: ['HRS9531'],
            aliases: ['HRS9531', 'HRS-9531'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual Peptide GLP-1/GIP Agonist',
            owner: 'Hengrui Pharma',
            ownerType: 'Chinese Biotech',
            partner: 'Kailera (US)',
            phase: 'Phase 3',
            status: 'Active',
            leadIndication: 'Obesity',
            otherIndications: ['T2D'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Kailera US rights deal',
                upfront: 0,
                milestones: 6000,
                partner: 'Kailera',
                territory: 'US rights',
                notes: '$6B potential deal with Kailera',
                hasBreakdown: false,
            },
            trialIds: [],
            keyData: 'Phase 3: ~18% weight loss at 48 weeks',
            notes: 'China-focused; Kailera has US rights',
            differentiator: 'China leader; large US deal validates asset',
        },
        // ========== PHASE 2 ==========
        {
            primaryName: 'Pemvidutide',
            codeNames: ['ALT-801'],
            genericName: 'pemvidutide',
            aliases: ['pemvidutide', 'ALT-801', 'ALT801'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual Peptide GLP-1/GCGR Agonist',
            owner: 'Altimmune',
            ownerType: 'Biotech',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'MASH, Obesity',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT05295875'],
            keyData: 'Phase 2: 80% liver fat reduction',
            notes: 'Focus on MASH indication',
            differentiator: 'MASH-focused; strong liver fat reduction',
        },
        {
            primaryName: 'Petrelintide',
            codeNames: ['ZP8396'],
            genericName: 'petrelintide',
            aliases: ['petrelintide', 'ZP8396'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Long-Acting Amylin Analog',
            owner: 'Zealand Pharma',
            ownerType: 'Biotech',
            partner: 'Roche',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Obesity',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Roche acquisition deal',
                upfront: 1650,
                milestones: 3650,
                partner: 'Roche',
                territory: 'Global',
                notes: '$1.65B upfront from Roche; up to $5.3B total',
                source: 'https://www.roche.com/media/releases/',
                hasBreakdown: true,
            },
            trialIds: [],
            keyData: 'Phase 1b: 8.6% at 16 weeks',
            notes: 'Non-GLP-1 mechanism; potential combo partner',
            differentiator: 'Amylin mechanism; Roche mega-deal validates; combo potential',
        },
        {
            primaryName: 'Aleniglipron',
            codeNames: ['GSBR-1290'],
            genericName: 'aleniglipron',
            aliases: ['aleniglipron', 'GSBR-1290', 'GSBR1290'],
            target: 'GLP-1',
            modality: 'Small Molecule',
            modalityDetail: 'Small Molecule GLP-1 Agonist',
            owner: 'Structure Therapeutics',
            ownerType: 'Biotech',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Obesity, T2D',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: ['NCT06052436'],
            keyData: 'Phase 2a: 6.2% weight loss at 12 weeks',
            notes: 'ACCESS trial data Dec 2025',
            differentiator: 'Oral small molecule; M&A target',
        },
        {
            primaryName: 'Elecoglipron',
            codeNames: ['AZD5004'],
            genericName: 'elecoglipron',
            aliases: ['elecoglipron', 'AZD5004', 'AZD-5004'],
            target: 'GLP-1',
            modality: 'Small Molecule',
            modalityDetail: 'Small Molecule GLP-1 Agonist',
            owner: 'AstraZeneca',
            ownerType: 'Big Pharma',
            partner: 'Eccogene',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Obesity, T2D',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Licensed from Eccogene',
                partner: 'Eccogene (Shanghai)',
                territory: 'Global ex-China',
                hasBreakdown: false,
            },
            trialIds: [],
            keyData: 'Phase 1: 5.8% at 4 weeks',
            notes: 'Vista/Solstice trials; data expected late 2025',
            differentiator: 'AstraZeneca backing; oral small molecule',
        },
        {
            primaryName: 'CT-388',
            codeNames: ['CT-388'],
            aliases: ['CT-388', 'CT388'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual Peptide GLP-1/GIP Agonist',
            owner: 'Roche',
            ownerType: 'Big Pharma',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Obesity, T2D',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            keyData: 'Data pending',
            notes: 'Potential combination with petrelintide',
            differentiator: 'Roche internal; combo with petrelintide',
        },
        {
            primaryName: 'Efinopegdutide',
            codeNames: ['MK-6024', 'HM12525A'],
            genericName: 'efinopegdutide',
            aliases: ['efinopegdutide', 'MK-6024', 'MK6024', 'HM12525A'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual Peptide GLP-1/GCGR Agonist',
            owner: 'Merck',
            ownerType: 'Big Pharma',
            partner: 'Hanmi',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'MASH',
            otherIndications: ['Obesity'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Licensed from Hanmi',
                partner: 'Hanmi Pharmaceutical',
                hasBreakdown: false,
            },
            trialIds: [],
            keyData: '72.7% liver fat reduction vs 42.3% semaglutide',
            notes: 'Superior to semaglutide for liver fat',
            differentiator: 'Beat semaglutide head-to-head for MASH; Merck backing',
        },
        {
            primaryName: 'Amycretin',
            codeNames: ['NNC0487-0111'],
            genericName: 'amycretin',
            aliases: ['amycretin', 'NNC0487-0111'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual Peptide GLP-1/Amylin Agonist',
            owner: 'Novo Nordisk',
            ownerType: 'Big Pharma',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Obesity',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            trialIds: [],
            keyData: 'Phase 1: ~13% at 12 weeks (oral)',
            notes: 'Oral formulation showing promise',
            differentiator: 'Oral dual agonist; Novo next-gen',
        },
        {
            primaryName: 'BI 3034701',
            codeNames: ['BI 3034701'],
            aliases: ['BI 3034701', 'BI3034701'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Triple Agonist (GLP-1/GIP/GCGR)',
            owner: 'Boehringer Ingelheim',
            ownerType: 'Big Pharma',
            partner: 'Gubra',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'Obesity',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Partnership with Gubra',
                partner: 'Gubra',
                hasBreakdown: false,
            },
            trialIds: [],
            keyData: 'Phase 1 safety/efficacy positive',
            notes: 'Next-gen triple agonist',
            differentiator: 'Triple agonist; BI development',
        },
        // ========== PHASE 1/2 ==========
        {
            primaryName: 'Noiiglutide',
            codeNames: ['HRS-7535'],
            genericName: 'noiiglutide',
            aliases: ['noiiglutide', 'HRS-7535', 'HRS7535'],
            target: 'GLP-1',
            modality: 'Small Molecule',
            modalityDetail: 'Small Molecule GLP-1 Agonist',
            owner: 'Hengrui',
            ownerType: 'Chinese Biotech',
            partner: 'Kailera (US)',
            phase: 'Phase 2',
            status: 'Active',
            leadIndication: 'T2D, Obesity',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Part of Kailera $6B deal',
                partner: 'Kailera',
                territory: 'US rights',
                hasBreakdown: false,
            },
            trialIds: [],
            keyData: 'Phase 2: competitive weight loss data',
            notes: 'Oral small molecule',
            differentiator: 'Oral; part of mega Kailera deal',
        },
        {
            primaryName: 'MET-097i',
            codeNames: ['MET-097i'],
            aliases: ['MET-097i', 'MET097i'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'GLP-1 Agonist (Long-acting)',
            owner: 'Pfizer',
            ownerType: 'Big Pharma',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Obesity',
            otherIndications: ['T2D'],
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Metsera acquisition',
                upfront: 4900,
                partner: 'Metsera (acquired)',
                notes: '$4.9B Metsera acquisition',
                hasBreakdown: true,
            },
            trialIds: [],
            keyData: 'Data pending',
            notes: 'Part of Metsera acquisition',
            differentiator: '$4.9B acquisition validates; Pfizer backing',
        },
        {
            primaryName: 'SYH2082',
            codeNames: ['SYH2082'],
            aliases: ['SYH2082', 'SYH-2082'],
            target: 'GLP-1',
            modality: 'Other',
            modalityDetail: 'Dual GLP-1/GIP Agonist (Monthly)',
            owner: 'CSPC Pharmaceuticals',
            ownerType: 'Chinese Biotech',
            partner: 'AstraZeneca',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Obesity, T2D',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'AstraZeneca deal',
                upfront: 1200,
                milestones: 3500,
                partner: 'AstraZeneca',
                notes: '$1.2B upfront from AstraZeneca; $3.5B milestones; 8 programs total',
                hasBreakdown: true,
            },
            trialIds: [],
            keyData: 'Preclinical data positive',
            notes: 'Part of AZ-CSPC deal; 8 programs total',
            differentiator: 'Monthly dosing; part of mega AstraZeneca deal',
        },
        {
            primaryName: 'YP05002',
            codeNames: ['YP05002'],
            aliases: ['YP05002', 'YP-05002'],
            target: 'GLP-1',
            modality: 'Small Molecule',
            modalityDetail: 'Small Molecule GLP-1 Agonist',
            owner: 'YaoPharma',
            ownerType: 'Chinese Biotech',
            partner: 'Pfizer',
            phase: 'Phase 1',
            status: 'Active',
            leadIndication: 'Obesity',
            regulatory: { btd: false, odd: false, fastTrack: false, prime: false },
            deal: {
                headline: 'Pfizer deal',
                milestones: 1935,
                partner: 'Pfizer',
                notes: 'Up to $1.935B from Pfizer',
                hasBreakdown: false,
            },
            trialIds: [],
            keyData: 'Data pending',
            notes: "Pfizer's second obesity bolt-on deal",
            differentiator: 'Oral; Pfizer backing',
        },
    ],
    excludedDrugs: [
        // Generic diabetes drugs
        'metformin', 'glipizide', 'glyburide', 'glimepiride',
        'pioglitazone', 'rosiglitazone', 'sitagliptin', 'linagliptin',
        'saxagliptin', 'alogliptin', 'empagliflozin', 'dapagliflozin',
        'canagliflozin', 'insulin', 'insulin glargine', 'insulin lispro',
        // Common trial drugs
        'placebo', 'standard of care', 'lifestyle intervention',
    ],
    excludedSponsors: [],
};
// ============================================
// Target Database Registry
// ============================================
exports.TARGET_DATABASES = {
    'B7-H3': exports.B7H3_DATABASE,
    'B7H3': exports.B7H3_DATABASE,
    'CD276': exports.B7H3_DATABASE,
    'TL1A': exports.TL1A_DATABASE,
    'TNFSF15': exports.TL1A_DATABASE,
    'TL-1A': exports.TL1A_DATABASE,
    'GLP-1': exports.GLP1_DATABASE,
    'GLP1': exports.GLP1_DATABASE,
    'GLP-1R': exports.GLP1_DATABASE,
    'incretin': exports.GLP1_DATABASE,
};
/**
 * Calculate investment metrics for a set of assets
 * Uses committed (upfront + equity) as primary metric, not total potential
 */
function calculateInvestmentMetrics(assets) {
    let totalUpfront = 0;
    let totalEquity = 0;
    let totalMilestones = 0;
    let assetsWithDeals = 0;
    let assetsWithVerifiedDeals = 0;
    let largestDeal = { name: '', committed: 0, potential: 0, partner: '' };
    const phaseDistribution = {};
    const modalityBreakdown = {};
    const ownershipBreakdown = {};
    let btdCount = 0, oddCount = 0, primeCount = 0, fastTrackCount = 0;
    let phase3Count = 0, activeCount = 0;
    for (const asset of assets) {
        // Count regulatory designations
        if (asset.regulatory.btd)
            btdCount++;
        if (asset.regulatory.odd)
            oddCount++;
        if (asset.regulatory.prime)
            primeCount++;
        if (asset.regulatory.fastTrack)
            fastTrackCount++;
        // Phase distribution
        phaseDistribution[asset.phase] = (phaseDistribution[asset.phase] || 0) + 1;
        if (asset.phase === 'Phase 3' || asset.phase === 'Filed')
            phase3Count++;
        if (asset.status === 'Active')
            activeCount++;
        // Ownership
        ownershipBreakdown[asset.ownerType] = (ownershipBreakdown[asset.ownerType] || 0) + 1;
        // Modality
        if (!modalityBreakdown[asset.modality]) {
            modalityBreakdown[asset.modality] = { count: 0, committed: 0, potential: 0 };
        }
        modalityBreakdown[asset.modality].count++;
        // Deal metrics - calculate committed and potential
        if (asset.deal) {
            assetsWithDeals++;
            if (asset.deal.hasBreakdown)
                assetsWithVerifiedDeals++;
            const upfront = asset.deal.upfront || 0;
            const equity = asset.deal.equity || 0;
            const milestones = asset.deal.milestones || 0;
            const committed = upfront + equity;
            const potential = committed + milestones;
            // Store calculated values back on the deal
            asset.deal.committed = committed;
            asset.deal.totalPotential = potential;
            totalUpfront += upfront;
            totalEquity += equity;
            totalMilestones += milestones;
            modalityBreakdown[asset.modality].committed += committed;
            modalityBreakdown[asset.modality].potential += potential;
            // Track largest deal by committed value (actual money)
            if (committed > largestDeal.committed) {
                largestDeal = {
                    name: asset.primaryName,
                    committed,
                    potential,
                    partner: asset.deal.partner || '',
                };
            }
        }
    }
    const totalCommitted = totalUpfront + totalEquity;
    const totalPotential = totalCommitted + totalMilestones;
    return {
        totalCommitted,
        totalPotential,
        totalUpfront,
        totalEquity,
        totalMilestones,
        largestDeal,
        assetsWithBTD: btdCount,
        assetsWithODD: oddCount,
        assetsWithPRIME: primeCount,
        assetsWithFastTrack: fastTrackCount,
        phaseDistribution,
        modalityBreakdown,
        ownershipBreakdown,
        totalAssets: assets.length,
        curatedAssets: assets.length,
        assetsWithDeals,
        assetsWithVerifiedDeals,
        phase3Assets: phase3Count,
        activeAssets: activeCount,
    };
}
// ============================================
// Lookup Functions
// ============================================
function getTargetDatabase(target) {
    const normalizedTarget = target.toUpperCase().replace(/[-\s]/g, '');
    for (const [key, db] of Object.entries(exports.TARGET_DATABASES)) {
        if (key.toUpperCase().replace(/[-\s]/g, '') === normalizedTarget) {
            return db;
        }
        if (db.aliases.some(a => a.toUpperCase().replace(/[-\s]/g, '') === normalizedTarget)) {
            return db;
        }
    }
    return null;
}
function findKnownAsset(name, target) {
    const normalizedName = name.toLowerCase().replace(/[-\s]/g, '');
    const databases = target
        ? [getTargetDatabase(target)].filter(Boolean)
        : Object.values(exports.TARGET_DATABASES);
    for (const db of databases) {
        for (const asset of db.assets) {
            if (asset.primaryName.toLowerCase().replace(/[-\s]/g, '') === normalizedName)
                return asset;
            if (asset.genericName?.toLowerCase().replace(/[-\s]/g, '') === normalizedName)
                return asset;
            if (asset.codeNames.some(c => c.toLowerCase().replace(/[-\s]/g, '') === normalizedName))
                return asset;
            if (asset.aliases.some(a => a.toLowerCase().replace(/[-\s]/g, '') === normalizedName))
                return asset;
        }
    }
    return null;
}
function isExcludedDrug(name, target) {
    const normalizedName = name.toLowerCase().trim();
    const db = target ? getTargetDatabase(target) : null;
    const excludedDrugs = db?.excludedDrugs || exports.B7H3_DATABASE.excludedDrugs;
    return excludedDrugs.some(excluded => normalizedName.includes(excluded.toLowerCase()) ||
        excluded.toLowerCase().includes(normalizedName));
}
function getKnownAssetsForTarget(target) {
    const db = getTargetDatabase(target);
    return db?.assets || [];
}
function isTargetRelatedIntervention(interventionName, interventionDescription, target) {
    const db = getTargetDatabase(target);
    if (!db)
        return false;
    const searchText = `${interventionName} ${interventionDescription || ''}`.toLowerCase();
    const targetAliases = [db.target.toLowerCase(), ...db.aliases.map(a => a.toLowerCase())];
    for (const alias of targetAliases) {
        if (searchText.includes(alias.replace(/-/g, '')))
            return true;
        if (searchText.includes(alias))
            return true;
    }
    const knownAsset = findKnownAsset(interventionName, target);
    if (knownAsset)
        return true;
    return false;
}
//# sourceMappingURL=known-assets.js.map